Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-11-15FDA Approved: RISPERIDONE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for risperidone by Chartwell RX, LLC, related to the generic product's labeling.
-
FDA approval · 2011-11-15FDA Approved: RISPERIDONE — Supplemental Application (Westminster Pharmaceuticals, LLC)
FDA approves Westminster Pharmaceuticals' supplemental application for risperidone (generic), updating its approved status under an ANDA.
-
FDA approval · 2011-11-10FDA Approved: RISPERIDONE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for a generic risperidone product from Aurobindo Pharma Limited.
-
FDA approval · 2011-11-09FDA Approved: SEROQUEL — Supplemental Application (H2-Pharma, LLC)
The FDA approved a supplemental application for SEROQUEL (quetiapine) from H2-Pharma, LLC.
-
FDA approval · 2011-11-09FDA Approved: SEROQUEL XR — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA has approved a supplemental application for SEROQUEL XR (quetiapine) by AstraZeneca Pharmaceuticals LP. The approval pertains to mod…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2011-11-08FDA Approved: RISPERIDONE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application to approve a generic risperidone product from Amneal Pharmaceuticals LLC under ANDA 091384.
-
FDA approval · 2011-11-04FDA Approved: RISPERIDONE — Original Application (Jubilant Cadista Pharmacuticals Inc.)
FDA approved Jubilant Cadista's generic risperidone under an Original Application (ANDA 090839).
-
FDA approval · 2011-10-30FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Tegretol (carbamazepine) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2011-10-30FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Tegretol (carbamazepine) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2011-10-25Clinical Trial Update: Lamotrigine for Symptoms of Geriatric Bipolar Depression [Phase 3]
This Phase 3 clinical trial evaluating lamotrigine for symptoms of geriatric bipolar depression has completed and posted results. The study …
-
FDA approval · 2011-10-25FDA Approved: OLANZAPINE — Original Application (Torrent Pharmaceuticals Limited)
FDA approved the Original Application for olanzapine from Torrent Pharmaceuticals Limited, marking the introduction of a generic olanzapine …
-
FDA approval · 2011-10-24FDA Approved: OLANZAPINE — Original Application (Sandoz Inc)
FDA approved the Original Application for olanzapine from Sandoz Inc., making a generic olanzapine available (ANDA 201588).
-
FDA approval · 2011-10-24FDA Approved: OLANZAPINE — Original Application (Dr. Reddy's Laboratories Ltd.)
FDA approved an original generic application for olanzapine from Dr. Reddy's Laboratories Ltd.
-
FDA approval · 2011-10-24FDA Approved: OLANZAPINE — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original ANDA for generic olanzapine (olanzapine tablets). The product is indicated for schizophrenia and bipola…
-
FDA approval · 2011-10-24FDA Approved: OLANZAPINE — Original Application (Dr.Reddy's Laboratories Limited)
FDA approved Dr. Reddy's Laboratories Limited's original application for a generic olanzapine product (ANDA076534), enabling market entry of…
-
FDA approval · 2011-10-20FDA Approved: LITHOBID — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for LITHOBID (lithium carbonate) from ANI Pharmaceuticals, Inc.
-
FDA approval · 2011-10-20FDA Approved: LITHIUM CARBONATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for lithium carbonate submitted by Hikma Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS trial_result · 2011-10-19Clinical Trial Update: Heart Rate Variability of Patients With Bipolar Disorder in Subsyndromal Depressive Phase
This ClinicalTrials.gov update notes a completed trial studying heart rate variability in patients with bipolar disorder in a subsyndromal d…
-
FDA approval · 2011-10-06FDA Approved: LAMOTRIGINE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved Unichem Pharmaceuticals (USA), Inc.'s original application for lamotrigine, making a generic version available for treatmen…
-
FDA approval · 2011-09-29FDA Approved: LAMOTRIGINE KIT — Supplemental Application (OWP Pharmaceuticals, Inc.)
The FDA approved a supplemental application for the Lamotrigine Kit from OWP Pharmaceuticals, Inc., authorizing a supplemental marketing use…
-
FDA approval · 2011-09-29FDA Approved: LAMOTRIGINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Lamotrigine filed by Zydus Pharmaceuticals USA Inc. The approval indicates changes under the…
-
FDA approval · 2011-09-29FDA Approved: LAMOTRIGINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for lamotrigine from Aurobindo Pharma Limited under ANDA090401.
-
FDA approval · 2011-09-29FDA Approved: LAMOTRIGINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for Lamotrigine by Dr. Reddy's Laboratories Limited (ANDA076708), indicating a change related to the…
-
FDA approval · 2011-09-29FDA Approved: LAMOTRIGINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for Lamotrigine from Dr. Reddy's Laboratories Limited.
-
CLINICAL_TRIALS trial_result · 2011-09-28Clinical Trial Update: Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania [Phase 4]
Phase 4 study assessing functional connectivity in mood-regulating circuits for bipolar depression has completed.